Recombinant Bacille Calmette-Guerin Priming against Measles

Publisher Website
Google Scholar
Abstract
Live attenuated measles virus (MV) vaccines are ineffective in young infants because of neutralization by maternal antibody. An immunization strategy that may permit priming for T cell memory for MV in infants at or shortly after birth uses recombinant bacille Calmette-Guérin expressing the full-length MV nucleocapsid (N) protein (rBCG::N). C3H/He mice immunized with rBCG::N developed T cell responses and ELISA antibodies to the N protein and low levels of neutralizing antibody after intracranial infection with MV strain CAM/R40. There was considerable reduction in the virus titer recovered from brain homogenates, a decrease in the incidence and severity of histologic encephalitis, and a decrease in mortality in rBCG::N-primed C3H/He mice compared with control mice. Given the limitations of existing live attenuated MV vaccines, these results encourage the further testing of rBCG::N vaccines in primate models.

This publication has 0 references indexed in Scilit: